Comparison of Pycnogenol® and Daflon® in Treating Chronic Venous Insufficiency: A Prospective,Controlled Study

Abstract

The aim of this study was to investigate the clinical efficacy of oral Pycnogenol® (Horphag Research Ltd., UK) in patients with severe chronic venous insufficiency (CVI) in comparison to the combination of diosmin and hesperidin (Daflon®, Servier, France). A group of 86 patients with severe chronic venous insufficiency (CVI), venous hypertension, ankle swelling) and previous history of venous ulcerations received either oral Pycnogenol (capsules) 150 mg or 300 mg daily for 8 weeks or Daflon, 1000 mg/day. All patients completed the study without dropouts. At the end of the study, microcirculatory results indicated: a progressive decrease of skin flux at rest (RF); a significant decrease in capillary filtration (RAS); an improvement in the symptomatic venous score (ASLS); a reduction in edema; a significant improvement (increase) in pO₂ and a decrease in pCO₂ in the Pycnogenol group. A significant level of improvement was reached after 4 weeks of treatment in most patients (p < .05) of the Pycnogenol group while clinical improvement was significant only in 6 subjects in the Daflon group. The positive effects of treatment with Pycnogenol after 8 weeks were significantly larger in comparison with the Daflon group. In conclusion, this study confirms the fast clinical efficacy of Pycnogenol in patients with chronic venous insufficiency and venous microangiopathy and its superiority—considering the evaluated parameters—to the combination of diosmin and hesperidin.

Keywords

Venous microangiopathy Edema Pycnogenol®Diosmin and hesperidin Daflon Venous disease Chronic venous insufficiency Varicose veins

References

Belcaro G , Nicolaides AN , Stansby G (eds). The Venous Clinic. London: Imperial College Press; 1999.

De Sanctis MT , Cesarone MR , Incandela L , Belcaro G , Acerbi G. Methods of evaluation and quantification of microangiopathy in high perfusion microangiopathy (Chronic venous insufficiency and diabetic microangiopathy). J Cardiovasc Pharmacol Ther 2002;7 (suppl I):S3-S3.

Belcaro G , Nicolaides AN (eds). Noninvasive Investigations in Vascular Disease. London: Imperial College Press; 2001.

Almond NE. A laser Doppler blood flowmeter used to detect thermal entrainment in normal persons and patients with Raynaud’s phenomenon. In: Spence VA , Sheldon CD (eds.) Practical Aspects of Skin Blood Flow Measurement. London: Biological Engineering Society, 1985.

Anning ST. The cause and treatment of leg ulcers. Lancet 1952;ii:789-789.

Anning ST. Leg Ulcers. Their Causes and Treatment. London: J & A Churchill Ltd, 1954.

Anning ST. The historical aspect. In Dodd H , Cockett FB (eds). The Pathology and Surgery of the Veins of the Lower Limb. Edinburgh: Churchill-Livingstone, 1976.

Belcaro G. The role of transcutaneous PCO2 measurements in association with laser Doppler flowmetry in venous hypertension. Phlebology 1988;3:189-189.

Belcaro G , Grigg M , Rulo A , Nicolaides AN. Blood flow in the perimalleolar skin in relation to posture in patients with venous hypertension. Ann Vasc Surg 1989;1:5-5.

10.

Belcaro G , Christopoulos D , Nicolaides AN. Skin flow and swelling in postphlebitic limbs. Vasa 1989;18:136-136.

11.

Belcaro G , Nicolaides AN , Volteas N , Leon M. Skin flow, the venoarteriolar response and capillary filtration in diabetics. A three-year follow-up study. Angiology 1992; 43:490-490.

12.

Belcaro G , Bollinger A , Hoffman U , Nicolaides AN (eds). Laser Doppler Flowmetry. London: Med-Orion; 1994.

13.

Bollinger A , Jager K , Geser A , Sgier F , Seglis J. Transcapillary and interstitial diffusion of Na-Fluorescein in chronic venous insufficiency with white atrophy. Int J Microcirc 1982;I:5-5.

14.

Fagrell B. Local microcirculation in chronic venous incompetence and leg ulcers. Vasc Surg 1979;13:217-217.

15.

Fagrell B.

Microcirculatory disturbances: The final cause for venous leg ulcers?

Vasa 1982;11:101-101.

16.

Fagrell B. Problems using laser Doppler flowmetry on the skin in clinical practice. In: Belcaro G , Hoffman U , Nicolaides AN , Bollinger A (Eds). Laser Doppler. London: Med Orion; 1994:49-49.

17.

Franzeck U , Bollinger A , Huch R , Huch A. Transcutaneous oxygen tension and capillary morphologic characteristics and density in patients with chronic venous incompetence. Circulation 1984;70:806-806.

18.

Hendriksen O. Local reflex in microcirculation in human subcutaneous tissue. Acta Physiol Scand 1976;97:446-446.

19.

Rayman G , Hassan A , Tooke JE. Blood flow in skin of the foot related to posture in patients with diabetes mellitus. BMJ 1986;292:87-87.

20.

Thulesius O. Capillary filtration under normal and pathological conditions. Angiologia 1973;10:198-198.

21.

Rohdewald P. A review of the French maritime pine bark extract (Pycnogenol), a herbal medication with a diverse clinical pharmacology. Int J Clin Pharmacol Ther 2002;40:158-158.

22.

Schmidtke I , Schoop W. Le Pycnogénol: Thérapeutique médicamenteuse de l’ædème statique. J Suisse Med Glob 1995;3:114-114.

23.

Petrassi C , Mastromarino A , Spartera C. Pycnogenol® in chronic venous insufficiency. Phytomedicine 2000;7:383-383.

24.

Arcangeli P. Pycnogenol in chronic venous insufficiency. Fitoter 2000;71:236-236.

25.

Koch R. Comparative study of Venostasin® and Pycnogenol® for treatment in chronic venous insufficiency. Phytother Res 2002;16:1-1.

26.

Riccioni C , Sarcinella R , Izzo A , Palermo G , Liguori L. Efficacy of Troxerutine in association with Pycnogenol®in the treatment of venous insufficiency. Eur Bull Drug Res 2004;12(1):7-7.

27.

Cesarone MR , Belcaro G , Rohdewald P , et al. Prevention of edema in long flights with Pycnogenol®. Clin Appl Thromb Hemost 2005;11(3):289-289.

28.

Belcaro G , Cesarone MR , Rohdewald P , et al. Prevention of venous thrombosis in long-haul flights with Pycnogenol®. Clin Appl Thromb Hemost 2004;10(4):373-373.

29.

Belcaro G , Cesarone MR , De Sanctis MT , et al. Laser Doppler and transcutaneous oximetry: Modern investigations to assess drug efficacy in chronic venous insufficiency. Int J Microcirc Clin Exp 1995;(Suppl 1):45-45.

30.

Cesarone MR , Laurora G , De Sanctis MT , Belcaro G. Capillary filtration, ankle edema in patients with venous hypertension: Effects of Daflon. Angiology 1993;44(1):57-57.

31.

Ting AC , Cheng SW , Wu LL , Cheung GC. Clinical and hemodynamic outcomes in patients with chronic venous insufficiency after oral micronized flavonoid therapy. Vasc Surg 2001;35:443-443.

32.

Belcaro G. Efficacy of Daflon 500 on capillary filtration, laser Doppler, PO₂ and pCO₂ over a 6 months treatment period in 50 patients with CVI and edema. Protocol CL3-5682-086-ITA (data on file, unpublished).

33.

Informatore Farmaceutico, Edimed, OEMF, Milan 2001.

34.

Belcaro G. Venous hypertensive microangiopathy: evaluation with laser Doppler flowmetry. PhD Thesis. London: University College; 1997.

35.

Cesarone MR , Dugall M , Belcaro G. Dose ranging of flavonoids. V Forum Web J 2005;2:12-12.